The Motley Fool's health-care show, Market Checkup, focuses this week on cholesterol, one of America's most notable health-care concerns.
According to the CDC, approximately 71 million Americans have high cholesterol, and less than 50% actually get treated. High levels of LDL cholesterol, commonly known as "bad" cholesterol, can lead to dangerous health problems, including heart disease and high blood pressure. In the following segment, health-care analysts David Williamson and Max Macaluso discuss how sales of AstraZeneca's (AZN 0.28%) cholesterol-lowering statin Crestor are threatened by competing generic drugs.
